ABBV has given back a few dollars from last week's peak but remains up nearly 5% on the week at $225.42, and the most interesting development is not the price — it's a sharp divergence between options traders leaning more bullish than they have in months and a short position that has quietly accelerated to its fastest build in at least six weeks.
The options shift is the standout this week. The put/call ratio has dropped to 0.84, now more than two standard deviations below its 20-day average of 0.96. That is the most call-dominated reading since at least the 52-week low of 0.62, and the move happened in a single session — Monday's PCR was still at 0.94. The broader trend that previous notes flagged has now gone further: six weeks ago the PCR sat above 1.07, heavy with put protection. It has since fallen 23 points. Options traders are not just less defensive; they are now actively leaning into upside at a historically unusual clip. The borrow market offers no pushback on the short side. Availability remains effectively unlimited — nearly 987 million shares available to borrow, far above even the most elevated short position — and cost to borrow has collapsed to 0.25%, down more than 34% on the week and among the lowest readings of the past 30 days. There is no friction for anyone who wants to short this stock.
Yet the short position has been growing. SI climbed nearly 10% over the past week to 1.39% of the free float — still low in absolute terms, but the pace of build is notable. The monthly gain is now above 12%, and the short score has ticked up from 31.7 to 32.8 over the past ten days. None of this constitutes crowded positioning — at 1.4% of float, short interest remains well below any threshold that would make it a primary narrative — but the divergence with options is worth naming. Call buyers are adding exposure at the same time short sellers are incrementally rebuilding. The two camps are pulling in opposite directions, and neither has yet blinked.
The Street broadly sides with the call buyers. The consensus mean target of $253.55 implies roughly 12% further upside from the current price, with the bullish end of the range (Piper Sandler at $298, Morgan Stanley at $278) sitting well above the current level. Recent analyst moves since earnings in late April have skewed toward raising targets rather than cutting them — several firms lifted numbers after the Q1 beat, when the stock jumped 6.9% in a single session. The most recent action from Evercore ISI, which trimmed its target by a dollar to $235 in mid-May, is a marginal exception to the otherwise constructive trend. The forward earnings multiple of 14.9x has expanded about 1.3 turns over the past month, tracking the stock's rally. The 12-month forward EPS growth factor scores at the 99th percentile — meaning almost no large-cap biotech peer has stronger expected earnings momentum — while the dividend score ranks in the 98th percentile. The bull case centres on Skyrizi and Rinvoq momentum, raised guidance, and pipeline breadth in neuroscience and aesthetics. The residual bear case is less conviction and more caution about execution risk on line extensions and discretionary spending headwinds in aesthetics.
Institutional flows show Capital Research and Management adding more than 11.5 million shares in the most recent reporting period — by far the largest single holder change in the table. BlackRock and State Street also added modestly. Morgan Stanley trimmed by 2.2 million shares over the same period, but the net direction of institutional flow is clearly supportive.
The next scheduled catalyst is Q2 earnings on July 27. The prior two quarterly prints produced single-day gains of 6.9% and 0.03% respectively, both followed by further gains over five sessions — a consistent pattern of the stock holding or extending after results rather than fading them. With the stock now up more than 10% since Q1 results and call positioning at its most aggressive of the year, July 27 becomes less a question of whether momentum continues and more a test of whether the raised expectations embedded in current positioning can be validated by the numbers.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
